Mary M. Horowitz, MD, MS

Publications

• Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors.

  (Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, Bonfim C, De la Camara R, Chaudhri NA, Ciceri F, Correa C, Frutos C, Galeano S, Garderet L, Gonzalez-Ramella O, Greco R, Hamad N, Hazenberg MD, Horowitz MM, Kalwak K, Ko BS, Kodera Y, Koh MB, Liu K, McLornan DP, Moon JH, Neven B, Okamoto S, Pasquini MC, Passweg JR, Paulson K, Rondelli D, Ruggeri A, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Greinix H, Saber W, Aljurf M, Niederwieser D.) Haematologica. 2024 Oct 01;109(10):3282-3294 PMID: 38721749 PMCID: PMC11443380 SCOPUS ID: 2-s2.0-85199142319 05/09/2024

• SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.

  (Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA.) Clin Infect Dis. 2024 Aug 16;79(2):542-554 PMID: 38801746 PMCID: PMC11327798 SCOPUS ID: 2-s2.0-85201391712 05/27/2024

• Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.

  (Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T.) J Clin Oncol. 2024 Aug 10;42(23):2757-2768 PMID: 38701390 SCOPUS ID: 2-s2.0-85201029574 05/03/2024

• Reply to S. Fuji.

  (Levis MJ, Hamadani M, Horowitz MM, Chen YB, BMT CTN 1506 Investigators.) J Clin Oncol. 2024 Jul 31:JCO2401091 PMID: 39083722 SCOPUS ID: 2-s2.0-85201082528 07/31/2024

• Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.

  (Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB, BMT-CTN 1506/MORPHO Study Investigators.) J Clin Oncol. 2024 May 20;42(15):1766-1775 PMID: 38471061 PMCID: PMC11095884 SCOPUS ID: 2-s2.0-85193456124 03/12/2024

• Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients.

  (Shaw BE, Flynn KE, He N, Cusatis R, D'Souza A, Hamilton BK, Horowitz MM, Mattila D, Phelan R, Lee SJ, Brazauskas R.) Cancer. 2024 May 15;130(10):1826-1835 PMID: 38198511 PMCID: PMC11058023 SCOPUS ID: 2-s2.0-85181878144 01/10/2024

• Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.

  (Eapen M, Kou J, Andreansky M, Bhatia M, Brochstein J, Chaudhury S, Haight AE, Haines H, Jacobsohn D, Jaroscak J, Kasow KA, Krishnamurti L, Levine JE, Leung K, Margolis D, Yu LC, Horowitz MM, Kamani N, Walters MC, Shenoy S.) Am J Hematol. 2024 Apr;99(4):785-788 PMID: 38343182 PMCID: PMC10947844 SCOPUS ID: 2-s2.0-85185139592 02/12/2024

• Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.

  (McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, Bashey A, Lowsky R, Miklos DB, Hansen J, Westervelt P, Yanik G, Waller EK, Howard A, Blazar BR, Wallace PK, Reshef R, Horowitz MM, Maziarz RT, Levine JE, Mohammadpour H.) Bone Marrow Transplant. 2024 Mar;59(3):334-343 PMID: 38110620 PMCID: PMC10961739 SCOPUS ID: 2-s2.0-85180197872 12/19/2023

• Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.

  (Fein JA, Shouval R, Krieger E, Spellman SR, Wang T, Baldauf H, Fleischhauer K, Kröger N, Horowitz M, Maiers M, Miller JS, Mohty M, Nagler A, Weisdorf D, Malmberg KJ, Toor AA, Schetelig J, Romee R, Koreth J.) Blood Adv. 2024 Feb 13;8(3):581-590 PMID: 38052043 PMCID: PMC10837477 SCOPUS ID: 2-s2.0-85185534011 12/06/2023

• SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).

  (Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA.) medRxiv. 2024 Jan 25 PMID: 38343800 PMCID: PMC10854344 02/12/2024

• Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study

  (Eapen M, Antin JH, Tolar J, Arai S, Horwitz ME, Kou J, Leifer E, McCarty JM, Nakamura R, Pulsipher MA, Rowley SD, Horowitz MM, Deeg HJ.) eClinicalMedicine. October 2024;76 SCOPUS ID: 2-s2.0-85202953543 10/01/2024

• Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

  (McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, Bashey A, Lowsky R, Miklos DB, Hansen J, Westervelt P, Yanik G, Waller EK, Howard A, Blazar BR, Wallace PK, Reshef R, Horowitz MM, Maziarz RT, Levine JE, Mohammadpour H.) Bone Marrow Transplantation. March 2024;59(3):334-343 SCOPUS ID: 2-s2.0-85180197872 03/01/2024